China BTK Challenger Enters Western Markets
InnoCare presented more than 40 orelabrutinib studies at EHA 2026, including the first treatment-naive CLL/SLL clinical data from US and European patients.
InnoCare Pharma
InnoCare presented more than 40 orelabrutinib studies at EHA 2026, including the first treatment-naive CLL/SLL clinical data from US and European patients.
